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Introduction 
Among the world’s most dangerous superbugs are multidrug resistant (MDR) bacteria of the 
so-called ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species) group1,2. The proportion of these 
bacteria in common urinary, pulmonary, skin and bloodstream infections has increased recently 
notably in recent years. Moreover, patients with vascular prostheses, indwelling catheters, 
dialysis shunts, etc., are particularly vulnerable to the virtually untreatable infections resulting 
from ESKAPE colonization and subsequent biofilm formation. 
S. aureus expresses toxins, enzymes, adhesins and several surface proteins which together 
promote the survival of this bacterium on tissues and other substrates and protect it from 
elimination by the immune system. Previously, S. aureus infections were treated with penicillin, 
but the The indiscriminate use of this antibiotic penicillin has increased the percentage of S. 
aureus penicillin-resistant strains to nearly 100% in some countries3. The same is true for several 
other antibiotics. 
Overexpression of penicillin-binding protein 2A (PBP2a), the most abundant PBP in MRSA 
strains with low affinity for β-lactams, enables these bacteria to survive in the presence of high 
concentrations of β-lactams, including methicillin4. Vancomycin, the antimicrobial usually 
chosen for the treatment of MRSA infections, is becoming increasingly ineffective, as Isolates 
with intermediate or full resistance to vancomycin emerge5. Instead, antimicrobial peptides 
(AMPs) such as daptomycin, an anionic lipopeptide consisting of a peptide core and a lipid tail, 
have become very important drugs in the treatment of gram-positive infections. Nonetheless, 
strains resistant to AMPs have been recently identified.  
Amphipathic polymyxins are cationic non-ribosomal antimicrobial polypeptides (CAMPs) 
produced by Paenibacillus polymyxa and available as antimicrobials since 1949. Their use was 
were abandoned because of their nephrotoxicity and neurotoxicity6. However, colistin and 
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polymyxin B have recently been rescued to treat infections caused by MDR gram-negatives, 
mainly Pseudomonas aeruginosa and Acinetobacter baumanii7. While polymyxins interact with the 
negatively charged outer membrane of gram-negative bacteria8, their mechanisms of action may 
additionally include alterations in ribosome binding, respiration, cell division, cell structure and 
the production of reactive oxygen species9. Gram-positives bacteria, by contrast, lack an outer 
membrane and are thus naturally resistant to polymyxins. 
A theoretically unlimited number of molecules with antimicrobial activity can be synthesized 
and/or modified in the laboratory; but the The synthesis of new molecules less toxic and with 
greater activity than conventional antibiotics is challenging. One strategy is to make small 
changes in known molecules, such as polymyxin, to generate derivatives effective against gram-
positive bacteria. The Our aim of this study was to explore the antimicrobial activity of two 
novel synthetic cyclolipopeptide analogues of polymyxin (CAMP113 and CAMP207) against S. 
aureus10 and other gram-positive bacteria 
Material and Methods 
Bacterial strains and growth conditions. The Clinical S.taphylococcus aureus Strains isolated at 
Laboratori de Referencia de Catalunya (Prat de Llobregat, Barcelona, Spain) and used in this 
study are reported as supplementary data. S. aureus ATCC 29213 and ATCC MRSA 700698 
served as a control strains in susceptibility tests. Muller-Hinton (MH, Becton, Dickinson and 
Company, San Agustin de Guadalix, Madrid, Spain) was used to determine minimum 
inhibitory concentrations (MICs) and minimal biofilm eradication concentrati ns (MBECs), 
tryptic soy agar (TSA) was used for the determination of colony countings in time-kill assays. , 
tryptic soy broth (TSB) with 0.25% glucose for biofilms were obtained in tryptic soy broth 
supplemented with 0.25% glucose (TSB-G). All bacteria were routinely cultured in and TSB (all 
media were from Scharlau Microbiology, Sentmenat, Spain). Colistin sulfate was supplied by 
Zhejiang Shenghua Biok Biology Co., Ltd., (Shanghai, China). Vancomycin, linezolid, 
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erythromycin, tetracycline and ciprofloxacin other antibiotics were obtained from Sigma-
Aldrich (Madrid, Spain). The cyclopolypeptides CAMP207 and CAMP113 were synthesized in 
our laboratory as described below. 
Peptide synthesis and purification. Peptides CAMP113 and CAMP207 were synthesized 
manually following standard Fmoc/tBu ref procedures and using DIPCDI/HOBt activation on a 
Rink amide resin. After the sequence was assembled, the peptides were cleaved from the resin 
by acidolysis for 90 min using trifluoroacetic acid (TFA)/triisopropylsilane/water (95:3:2, v/v). 
TFA was removed with a stream of nitrogen gas. The oily residue was treated with dry diethyl 
ether, and the precipitated peptide was isolated by centrifugation. The homogeneity of the 
crude peptide was assessed by analytical HPLC on Nucleosil C18 reverse-phase columns (4 mm 
× 250 mm, 5-µm particle diameter, 120Å pore size). Elution was carried out at a flow rate of 1 
mL·min−1 in solutions of 0.045% TFA and acetonitrile containing 0.036% TFA, with UV detection 
at 220 nm. The peptides were cyclized in an aqueous solution of 5% dimethylsulfoxide for 24 h 
and lyophilized twice. The peptide was subsequently purified by preparative HPLC on a 
Waters DeltaPrep 3000 system with a Phenomenex C18 10–13 column (250 mm× 10 mm, 5-µm 
particle diameter), elution with H2O/acetonitrile/0.1% TFA gradient mixtures and UV detection 
at 220 nm. Final purity was >99% according to analytical HPLC. The peptides were and 
characterized by matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass 
spectrometry using a PerSeptive Biosystems Voyager-DE instrument. MALDI-TOF MS: m/z 
(C55H96N16O12S2): 1237.9 [M + H]+, 1259.7 [M + Na]+, 1275.7 [M + K]+, 1219.9 [M − H2O]+ 
(Figure 1)10 
MIC Determination. A Broth microdilution method was used to determine the MICs. The 
results were and interpreted according to the European Committee on Antimicrobial 
Susceptibility Testing EUCAST guidelines 14. 
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Time-kill curves and growth curves. Killing-curves assays were performed obtained with a 
starting inoculuma of 5 × 105 colony-forming units (CFU)/mL. Bacterial strains were tested 
against CAMP113 and CAMP207 at concentrations above and below the MICs. Antimicrobials 
were added to 10 mL of exponentially growing bacterial cultures incubated at 37°C with 
shaking. Samples were retrieved aseptically at 1, 2, 4 and 6 h, diluted in Ringers ¼ and plated 
on TSA for colony counting. The response of microbial strains to a single antimicrobial was 
determined based on a logarithmic decrease in viable bacteria. The effect of CAMPs on the 
growth of clinical S. aureus was assayed with a starting inoculuma of 106 and 108 CFU/mL 
respectively. 
MBEC Determination. A modification of the procedure described by Moskowitz et al. 15 was 
used to determine MBECs as previously described11.  
Toxicity of peptides on human hepatocytes. Colistin, CAMP113 and CAMP207 and colistin 
sulfate were assayed for in vitro toxicity against human hepatocytes using the (HepG2) cell line. 
as previously described ref. In brief, the cells were seeded at 1.5 × 104/well in a 96-well cell plate 
(WWR Int, LLC, Radnor, PA) in RPMI (Biochrom AG, Berlin, Germany) supplemented with 
10% fetal bovine serum. After incubation of the plates for 24 h at 37°C and 5% CO2, the cells 
were treated for 24 h with different concentrations of antimicrobials (500, 250, 100, 50, 5 mg/L), 
followed by incubation for 24 h with 200 µL of 70 µM RPMI containing resazurin sodium salt 
(Sigma Aldrich MO, USA). The fluorescence resulting from the conversion by viable cells of 
resazurin to fluorescent resorufin was then measured in an ELISA microplate reader (FLUOstar 
OPTIMA, BMG LABTECH, Germany) at an emission wavelength of 590 nm and an excitation 
wavelength of 530 nm. 
Confocal laser scanning microscopy imaging. Biofilms on an 8-well glass slide were washed 
once with Ringer ¼ to remove unfixed bacteria and then treated with antimicrobials at the 
selected concentration. After 4 h of incubation at (37°C), the biofilms were rinsed once with 
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Ringer ¼ and stained using the Live/Dead BacLight kit (TermoFisher, Eugene, Oregon, USA) 
following the manufacturer´s guidelines. Fluorescence was observed using a Leica TCS-SL 
filter-free spectral confocal laser-scanning microscope (Leica Microsystems, Mannheim, 
Germany) equipped with a 488-nm argon laser, 543-nm and 633-nm He/Ne lasers (Scientific and 
Technological Centers, University of Barcelona, Spain). All experiments were performed in 
duplicate. The images were analyzed using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). The percentages of live and dead bacterial cells were calculated from the 
total cell number. 
Results and Discussion 
In this study, in In an effort to produce new molecules with enhanced antimicrobial capacity, 
we simplified colistin by adding a disulfide bond between two cysteine residues, which 
facilitated subsequent synthetic steps. Concurrently, based on the scaffold of polymyxins, both 
Both, Peptides CAMP113 and CAMP207  have a disulfide bond between two cysteine residues 
were modified such that both, contained a dodecanoyl chain instead of (S)-6-methyloctanoyl, 
CAMP113 and CAMP207 have a Cys residue at position 4, Norleucine (NLe) at position 7 and 
(D)-Cys at position 11, instead whereas polymyxin E has a 2,4-Diaminobutyric Acid (Dab),  a 
residue at position 4, Leu at position 7 and Thr at position 11 of polymyxin. CAMP113 was 
further modified with (D)-Phe and CAMP207 with (D)-(4F)-Phe instead of Leu at position 6. In 
addition, an Arg was substituted at position 8 of CAMP113 whereas colistin contains Dab 
(Figure 1). 
Polymyxin action involves interaction with lipid A. The mechanism of action of polymyxins is 
thought to involve their direct interaction with the lipid A component of lipopolysaccharide 
(LPS)16 and the displacement of the divalent cations (Mg2+ and Ca2+) bridging adjacent 
lipopolysaccharide (LPS) molecules.17 The minimum inhibitory concentration (MICs) of both 
CAMP113 and CAMP207 peptides is 4 mg/L. The Tested strains were fully resistant to colistin 
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(> 512 mg/L) and susceptible to vancomycin (1–0.5 mg/L), with the exception of the 
vancomycin-resistant isolate but SasVR (Table 1 supplementary data). Thus, the activity of the 
two CAMPs was 128 times higher than that of colistin (Table 1) being MICs within the clinical 
use range. However, the main limitation of MIC values as an indicator is that they represent 
only the cumulative effect at 18 h, rather than the time course of activity. By contrast, while 
time-kill kinetics or growth curves describe the antimicrobial action of the test compound while 
providing insights into the events during its first hours of contact with the tested strains. Thus, 
we conducted Time-kill curves assays to depicting the biological behaviour over time of 
different clinical strains incubated with CAMP113 and CAMP207. The results revealed that, 
Despite their chemical similarities, the colistin- and polymyxin-derived CAMPs they differed in 
their actions, as described below, but both peptides were effective in killing killed the bacteria 
in a concentration-dependent manner (Figure 2.) being Moreover, their behaviour of each 
compound was very similar irrespective of the strain tested. 
Two types of responses were observed in the presence of CAMPs: either the bacterium was 
completely inhibited at all concentrations tested or inhibition was achieved only at high 
concentrations (Figure 2). Neither peptide was able to fully eradicate the bacteria solely as a 
function of its concentration; rather, the activities of the two CAMPs strongly depended on the 
bacterial strain. For example, CAMP113 fully eradicated strain SaS06 (2A) in 1 h at 16 mg/L, in 2 
h at 8 mg/L, but a few individuals survived at 4 mg/L whereas strain SaS16 was completely 
eradicated at this latter concentration (Figure 2B). At a concentration of 8 mg/L or higher, 
CAMP113 produced the rapid death of strain SaS16 (2C), during the first hour whereas at an 
equal concentration of CAMP207 (Figure 2D) 2 h were required. At 4 mg/L, both peptides 
required 4 h to fully kill strain SaS16. In tests of strain SaS18, complete eradication was achieved 
within 4 h (Figure 2E) using 8 µg CAMP113/mL but within 6 h using the same concentration of 
CAMP207 (Figure 2F). However, even at 4 mg /mL, CAMP207 completely failed in SaS18 
eradication. Similar outcomes were obtained with the remainder of the tested strains.  
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Figure 2 also shows representative growth curves. With inocula up to 2 × 106  colony-forming 
units (CFU)/mL, growth was fully prevented irrespective of the CAMP and the concentration 
tested (4, 8 or 16 mg/L). By contrast, with Higher inocula (up to 2 × 108 CFU/mL) gave initial 
growth of the strain was delayed at 4 mg/L, and a longer delay effect that was much more 
apparent at 8 mg/L. Finally, both CAMPs were able to fully inhibit growth at concentrations of 
16 mg/L, thus demonstrating the concentration-dependence. of high-density inocula.  
S. aureus, like other bacteria causing infection, have evolved mechanisms to evade innate host 
defences defenses. These mechanisms includinge proteolysis against of natural peptides, 
secretion of lytic enzymes, modulation of the electrical charge of the cell surface to enhance 
repulsion, and biofilm formation18. As the main virulence factor of S. aureus and many other 
bacterial species 19, Biofilms have been the focus of considerable research attention and their 
destruction the main goal of current antibacterial therapy. The ability of a compound to reduce 
the survival of bacteria within biofilms can be quantitatively evaluated by determining the 
minimal biofilm eradication concentration (MBEC), as shown for the CAMPs in Figure 2. The 
MBECs of both CAMPs indicated the ability of these compounds to fully eradicate S. aureus 
biofilms at relatively low concentrations, in contrast to colistin, which had no effect. Confocal 
imaging (Figure 2) revealed the effects of the CAMPs (at 128 mg/L) on S. aureus biofilm during 
short exposure periods (4 h). No significant death occurred in either the controls or colistin-
treated biofilms, whereas CAMP113 (5C) and CAMP207 (5D) were able to kill roughly one half 
the bacteria within the biofilm (47.27% and 50.46%, respectively). Given the current interest in 
CAMPs in the search for new approaches in anti-biofilm treatment 20, our study demonstrates 
the potency of these two cyclic peptides analogues of polymyxin in targeting biofilms harboring 
several clinical isolates of S. aureus. Under conditions in which a colistin dose of 2,048 mg/L was 
required, CAMP113 and CAMP207 eradicated the biofilms of all strains tested at much lower 
concentrations (Figure 2). 
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The CAMPs were also tested for their cytotoxicity towards the human hepatocellular cell line 
HepG2 (ATCC, American Type Culture Collection HB8065). As shown in Figure 2d, colistin 
had a relative low cytotoxicity in vitro since its mechanism of toxicity involves the accumulation 
of molecule in organs such as the kidney. At 5 mg/L, a slightly higher concentration than the 
MICs of the CAMPs, none of the tested compounds had detectable toxicity. A concentration of 
50 mg/L yielded 89.49% HepG2 cell viability for colistin and 67.03% and 62.62% for CAMP113 
and CAMP207, respectively. At 100 mg/L, colistin resulted in 68.75% HepG2 viability, 
CAMP113 in 53.2% and CAMP207 in 57.3%. At an antimicrobial concentration of 250 mg/L, 
HepG2 viability was 51.05%, 16.01% and 8.29%, respectively. At 500 mg/L, while 38.39% of the 
cells survived in the presence of colistin both CAMP113 and CAMP207 were highly toxic (7.74% 
and 7.4%, respectively) (Figure 3). Nonetheless, the selectivity index (the relationship between 
the IC50 and the MIC) in S. aureus strains 21 was inordinately high for the peptides (21.25 for 
CAMP113 and 23.75 for CAMP207 vs. 0.36 for colistin); that is, CAMP113 and CAMP207 are 
much more selective than colistin because the concentrations needed to kill the bacteria are 
much lower. Moreover, colistin is nephrotoxic, as it increases tubular epithelial cell membrane 
permeability to cations, anions and water, leading to cell swelling and cell lysis 22. The presence 
in the newly synthesized CAMPs of a disulfide bond facilitates their biodegradation and thus 
avoids their accumulation in the kidney. This is in agreement with previous studies, in which 
the lethal dose (LD50) for peptides of this family in CD-1 mice was 283 mg/kg, compared to the 
59.5 mg/kg determined for polymyxin. 
The emergence of MDR strains of several bacterial species has posed a tremendous challenge in 
clinical practice and has renewed interest in polymyxins, whose activity against gram-negatives 
bacteria is well established. Colistin is considered the drug of last-resort in the treatment of 
gram-negative-MDR bacteria such as P. aeruginosa, A. baumanii and K. pneumoniae23,24. 
Nonetheless polymyxins are intrinsically inactive against gram-positive bacteria because they 
lack lipid A, the primary binding site of polymyxins16,23,25 
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Novel peptides have been synthesized in an attempt to evade the increasing polymyxin 
resistance of gram-negative bacteria. Some of these peptides have low MIC values in gram-
positives species 8,26. Similarly, our peptides showed activity against gram-positive S. aureus. 
Teichoic acids have a chemical structure similar to that of the LPS regions to which polymyxins 
bind15. To determine whether teichoic acids were the targets of CAMP113 and CAMP 207, we 
performed isothermal titration calorimetry experiments. The results showed a three-step 
reaction between the peptides and teichoic acid, two of which were exergonic and the third 
endergonic (Figure 4). 
To examine the spectrum of action of the CAMPs studied, we explored their action against 
gram-positive Streptococcus pneumoniae. Our results showed that in this species the MIC of 
colistin was consistently > 32 mg/L, whereas the MICs of both peptides were between 2 and 4 
mg/L depending on the isolate. Together with the above-described results in the S. aureus 
isolate SasVR, a confirmed superbug resistant to vancomycin and linezolid (two new-
generation antibiotics of choice in the treatment of MDR staphylococci).  
Conclusions 
Polymyxins, are regarded as inactive against gram-positives bacteria. In this study, we showed 
that after some small changes in polymyxin molecule confers have activity against S. aureus and 
S. pneumoniae. Our study demonstrates that Peptides of this type, despite a more detailed 
determination of in vitro and in vivo toxicity as well as the development issues have to be 
addressed,  may open up new frontiers in the treatment of “untreatable infections.”  
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Introduction 
Among the world’s most dangerous superbugs are multidrug resistant (MDR) bacteria of the 
so-called ESKAPE group1,2. The proportion of these bacteria in common infections has increased 
recently3. Moreover, patients with vascular prostheses, indwelling catheters, dialysis shunts, 
etc., are particularly vulnerable to the virtually untreatable infections resulting from ESKAPE 
colonization and subsequent biofilm formation. 
The indiscriminate use of penicillin has increased the percentage of S. aureus penicillin-resistant 
strains to nearly 100 %4. The same is true for several other antibiotics. 
Overexpression of penicillin-binding protein 2A (PBP2a), in MRSA enables to survive in the 
presence of high concentrations of β-lactams, including methicillin5. Isolates with intermediate 
or full resistance to vancomycin emerge4. Instead, antimicrobial peptides (AMPs) have become 
very important drugs in the treatment of gram-positive infections. Nonetheless, strains resistant 
to AMPs have been recently identified.  
Amphipathic polymyxins are cationic non-ribosomal antimicrobial polypeptides (CAMPs) 
produced by Paenibacillus polymyxa available as antimicrobials since 1949 abandoned because of 
their nephrotoxicity and neurotoxicity6. However, colistin and polymyxin B have recently been 
rescued to treat infections caused by MDR gram-negatives, mainly Pseudomonas aeruginosa and 
Acinetobacter baumanii7. While polymyxins interact with the negatively charged outer membrane 
of gram-negative bacteria8, their mechanisms of action may additionally include alterations in 
ribosome binding, respiration, cell division, cell structure and the production of reactive oxygen 
species9. Gram-positives lack outer membrane and are thus naturally resistant to polymyxins. 
The synthesis of new molecules less toxic and with greater activity than conventional antibiotics 
is challenging. One strategy is to make small changes in known molecules, such as polymyxin, 
to generate derivatives effective against gram-positive bacteria. The antimicrobial activity of 
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two novel synthetic cyclolipopeptide analogues of polymyxin (CAMP113 and CAMP207) 
against S. aureus and other gram-positive bacteria is reported.  
Material and Methods 
Bacterial strains and growth conditions. Clinical S. aureus strains are reported as 
supplementary data. S. aureus ATCC 29213 and ATCC MRSA 700698 served as a control. 
Muller-Hinton (MH, Becton, Dickinson and Company, Madrid, Spain) to determine minimum 
inhibitory concentrations (MICs) and minimal biofilm eradication concentrations (MBECs), 
tryptic soy agar (TSA) for colony counting, tryptic soy broth (TSB) with 0.25% glucose for 
biofilms and TSB were from Scharlau Microbiology, Sentmenat, Spain. Colistin sulfate was 
supplied by Zhejiang Shenghua Biok Biology Co., Ltd., (Shanghai, China). Other antibiotics 
were from Sigma-Aldrich (Madrid, Spain). The cyclopolypeptides CAMP207 and CAMP113 
were synthesized in our laboratory as described below. 
Peptide synthesis and purification. Peptides CAMP113 and CAMP207 were synthesized 
manually following standard Fmoc/tBu and characterized by matrix-assisted laser desorption 
ionization time of flight (MALDI-TOF) mass spectrometry using a PerSeptive Biosystems 
Voyager-DE instrument. MALDI-TOF MS: m/z (C55H96N16O12S2): 1237.9 [M + H]+, 1259.7 [M 
+ Na]+, 1275.7 [M + K]+, 1219.9 [M − H2O]+ (Figure 1)10. 
MIC Determination. Broth microdilution was used and interpreted according to the European 
Committee on Antimicrobial Susceptibility Testing EUCAST guidelines11. 
Time-kill curves and growth curves. Killing-curves were obtained with a starting inocula of 5 × 
105 colony-forming units (CFU)/mL against CAMP113 and CAMP207. Antimicrobials were 
added to exponentially growing bacteria at 37°C with shaking. Samples were retrieved 
aseptically at 1, 2, 4 and 6 h, diluted in Ringers ¼ and plated on TSA. The response to a single 
antimicrobial was determined based on a logarithmic decrease in viable bacteria. The effect of 
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CAMPs on the growth of clinical S. aureus was assayed with starting inocula of 106 and 108 
CFU/mL. 
MBEC Determination. A modification of the procedure described by Moskowitz et al. was 
used to determine MBECs as previously described11. 
Toxicity of peptides on human hepatocytes. Colistin, CAMP113 and CAMP207 were assayed 
for in vitro toxicity against human hepatocytes (HepG2) as previously described12. 
Confocal laser scanning microscopy imaging. Biofilms were washed with Ringer ¼ and 
treated with antimicrobials. After 4 h incubation (37°C), biofilms were rinsed with Ringer ¼ and 
stained using the Live/Dead BacLight kit (TermoFisher, Eugene, Oregon, USA). Fluorescence 
was observed using a Leica TCS-SL filter-free spectral confocal laser-scanning microscope 
(Leica Microsystems, Mannheim, Germany) equipped with a 488-nm argon laser, 543-nm and 
633-nm He/Ne lasers. All experiments were performed in duplicate. The images were analyzed 
using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The percentages of 
live and dead bacterial cells were calculated from the total cell number. 
Results and Discussion 
Peptides CAMP113 and CAMP207 have a disulfide bond between two cysteine residues, 
contained a dodecanoyl chain instead of (S)-6-methyloctanoyl, have a Cys residue at position 4, 
Norleucine (NLe) at position 7 and (D)-Cys at position 11, instead 2,4-Diaminobutyric Acid 
(Dab), Leu and Thr of polymyxin. CAMP113 was further modified with (D)-Phe and CAMP207 
with (D)-(4F)-Phe instead of Leu at position 6. In addition, an Arg was substituted at position 8 
of CAMP113 whereas colistin contains Dab (Figure 1). 
Polymyxin action involves interaction with lipid A and the displacement of Mg2+ and Ca2+ 
bridging adjacent lipopolysaccharide (LPS) molecules13. MIC of both peptides is 4 mg/L. Tested 
strains were resistant to colistin (> 512 mg/L) and susceptible to vancomycin (1–0.5 mg/L), but 
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SasVR (supplementary data). The activity of the two CAMPs was high (Table 1) being MICs 
within the clinical use range.  MIC values represent only the cumulative effect at 18 h, rather 
than the time course of activity, while time-kill kinetics or growth curves describe the 
antimicrobial action providing insights into the events during its first hours depicting the 
biological behaviour over time.  Despite their chemical similarities both peptides killed the 
bacteria in a concentration-dependent manner (Figure 2.) being their behaviour very similar 
irrespective of the strain tested. 
Two types of responses were observed in the presence of CAMPs: either the bacterium was 
completely inhibited at all concentrations tested or inhibition was achieved only at high 
concentrations (Figure 2). Neither peptide was able to fully eradicate the bacteria solely as a 
function of its concentration; rather, the activities of the two CAMPs strongly depended on the 
bacterial strain. For example, CAMP113 fully eradicated strain SaS06 (2A) in 1 h at 16 mg/L, in 2 
h at 8 mg/L, but a few individuals survived at 4 mg/L whereas strain SaS16 was completely 
eradicated at this latter concentration (Figure 2B). At a concentration of 8 mg/L or higher, 
CAMP113 produced the rapid death of strain SaS16 (2C), during the first hour whereas at an 
equal concentration of CAMP207 (Figure 2D) 2 h were required. At 4 mg/L, both peptides 
required 4 h to fully kill strain SaS16. In tests of strain SaS18, complete eradication was achieved 
within 4 h (Figure 2E) using 8 µg CAMP113/mL but within 6 h using the same concentration of 
CAMP207 (Figure 2F). However, even at 4 mg /mL, CAMP207 completely failed in SaS18 
eradication. Similar outcomes were obtained with the remainder of the tested strains.  
Figure 2 also shows representative growth curves. With inocula up to 2 × 106   (CFU)/mL, 
growth was fully prevented irrespective of the CAMP and the concentration tested (4, 8 or 16 
mg/L). Higher inocula (up to 2 × 108 CFU/mL) gave initial growth delay at 4 mg/L, and a longer 
delay at 8 mg/L. Finally, both CAMPs were able to fully inhibit growth at concentrations of 16 
mg/L, demonstrating the concentration-dependence.  
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S. aureus have evolved mechanisms to evade innate host defenses including proteolysis of 
natural peptides, secretion of lytic enzymes, modulation of the electrical charge of the cell 
surface to enhance repulsion, and biofilm formation14. Biofilms have been the focus of 
considerable research attention and their destruction the main goal of current antibacterial 
therapy. The MBECs of both CAMPs indicated the ability of these compounds to fully eradicate 
S. aureus biofilms at relatively low concentrations, in contrast to colistin, which had no effect. 
Confocal imaging (Figure 2) revealed the effects of the CAMPs (at 128 mg/L) on S. aureus 
biofilm during short exposure periods (4 h). No significant death occurred in either the controls 
or colistin-treated biofilms, whereas CAMP113 (5C) and CAMP207 (5D) were able to kill 
roughly one half the bacteria within the biofilm (47.27% and 50.46%, respectively). Given the 
current interest in CAMPs in the search for new approaches in anti-biofilm treatment 15, our 
study demonstrates the potency of these peptides in targeting biofilms harboring several 
clinical isolates of S. aureus. Under conditions in which a colistin dose of 2,048 mg/L was 
required, CAMP113 and CAMP207 eradicated the biofilms of all strains tested at much lower 
concentrations (Figure 2). 
The CAMPs were also tested for their cytotoxicity towards the human hepatocellular cell line 
HepG2 (ATCC, American Type Culture Collection HB8065). As shown in Figure 2d, colistin 
had a relative low cytotoxicity in vitro since its mechanism of toxicity involves the accumulation 
of molecule in organs such as the kidney. At 5 mg/L, a slightly higher concentration than the 
MICs of the CAMPs, none of the tested compounds had detectable toxicity. A concentration of 
50 mg/L yielded 89.49% HepG2 cell viability for colistin and 67.03% and 62.62% for CAMP113 
and CAMP207, respectively. At 100 mg/L, colistin resulted in 68.75% HepG2 viability, 
CAMP113 in 53.2% and CAMP207 in 57.3%. At an antimicrobial concentration of 250 mg/L, 
HepG2 viability was 51.05%, 16.01% and 8.29%, respectively. At 500 mg/L, while 38.39% of the 
cells survived in the presence of colistin both CAMP113 and CAMP207 were highly toxic (7.74% 
and 7.4%, respectively) (Figure 3). Nonetheless, the selectivity index (the relationship between 
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the IC50 and the MIC) in S. aureus strains 16 was inordinately high for the peptides (21.25 for 
CAMP113 and 23.75 for CAMP207 vs. 0.36 for colistin); that is, CAMP113 and CAMP207 are 
much more selective than colistin because the concentrations needed to kill the bacteria are 
much lower. Moreover, colistin is nephrotoxic, as it increases tubular epithelial cell membrane 
permeability to cations, anions and water, leading to cell swelling and cell lysis17. The presence 
in the newly synthesized CAMPs of a disulfide bond facilitates their biodegradation and thus 
avoids their accumulation in the kidney. This is in agreement with previous studies, in which 
the lethal dose (LD50) for peptides of this family in CD-1 mice was 283 mg/kg, compared to the 
59.5 mg/kg determined for polymyxin10. 
The emergence of MDR strains of several species has posed a tremendous challenge in clinical 
practice and renewed interest in polymyxins, whose activity against gram-negatives is well 
established. Colistin is considered the drug of last-resort in the treatment of gram-negative-
MDR bacteria such as P. aeruginosa, A. baumanii and K. pneumoniae18,19. Nonetheless polymyxins 
are intrinsically inactive against gram-positive bacteria because they lack lipid A, the primary 
binding site of polymyxins18,20 
Novel peptides synthesized in an attempt to evade the increasing polymyxin resistance of 
gram-negative bacteria have low MIC values in gram-positive8. Similarly, our peptides showed 
activity against S. aureus. Teichoic acids have a chemical structure similar to that of the LPS 
regions to which polymyxins bind15. To determine whether teichoic acids were the targets of 
CAMP113 and CAMP 207, we performed isothermal titration calorimetry experiments. The 
results showed a three-step reaction between the peptides and teichoic acid, two of which were 
exergonic and the third endergonic (supplementary data). 
To examine the spectrum of action of the CAMPs studied, we explored their action against 
gram-positive Streptococcus pneumoniae. Our results showed that in this species the MIC of 
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colistin was consistently > 32 mg/L, whereas the MICs of both peptides were between 2 and 4 
mg/L depending on the isolate.  
Polymyxins, regarded as inactive against gram-positives after some small changes have activity 
against S. aureus and S. pneumonia; peptides of this type, despite a more detailed determination 
of in vitro and in vivo toxicity as well as the development issues have to be addressed, may open 
up new frontiers in the treatment of “untreatable infections.”  
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Figure 1. Chemical structure of the cyclopolypeptides CAMP113 and CAMP207 (below) and polymyxin B (above). 
Common structural and chemical features that were modified are highlighted in gray. Differences in the structural 
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Figure 2. Biological activity of CAMP113 and CAMP207. Control (•), 4 mg/L (○), 8 mg/L (▼), 16 mg/L (△). (A) Strain SaS06 
incubated with CAMP113. (B) Strain SaS06 incubated with CAMP207. (C) Strain SaS16 incubated with CAMP113. (D) Strain 
Sas16 incubated with CAMP207. (E) Strain Sas18 incubated with CAMP113. (F) Strain Sas18 incubated with CAMP207. G) 
growth curve of strain SaS16 (inoculum of 106 cfu/mL) in the presence of /CAMP113. H) Growth curve of strain SaS06 (inoculum 
of 108 CFU/mL) in the presence of /CAMP207. a) Minimal biofilm eradication concentration assays. Strain SaS06 (CAMP113, 128 
mg/L; CAMP207, 128 mg/L; colistin >2048 mg/L). Strain SaS16 (CAMP113, 32 mg/L; CAMP207, 32 mg/L; colistin >2048 mg/L). 
Strain SaS18 (CAMP113, 256 mg/L; CAMP207, 256 mg/L; colistin, >2048 mg/L); b) Percentage of biofilm death after 4 h of 
exposure. c) Confocal laser scanning microscopy assays. The images (1024 × 1024 pixels) were taken after 4 h of exposure to: 
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Antimicrobial susceptibility (minimum inhibitory concentration, MIC; mg/L).  

















4 4 >512 1(S) 4(S) 1-2(S) 1(S) 1(S)  
SaSVR *1Conj. 
exd 
2-4 4-8 >512 >32(R) >32(R) >32(R) 1-2 4(R)  
SaSVI *2Spleen 
nec. 
16 4-8 >512 2-4 4(S) >32(R) >32(R) 0,25-0,5(S)  
SaS01 Wound 
Smear 
4 4 >512 1(S) 4(S) 1(S) 1(S) 2-4(R)  
SaS02 Wound 
Smear 
4 4 >512 1(S) 4(S) 1(S) 1(S) 1(S)  
SaS03 Wound 
Smear 
4 4 >512 1(S) 4(S) >32(R) 0,5-1(S) 1(S)  
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 * MRSA. *
1




4 4 >512 0,5(S) 4(S) >32(R) 0,125(S) >32(R)  
SaS05* Wound 
Smear 
4 4 >512 0,5(S) 2(S) >32(R) >32(R) >32(R)  
SaS06* Sputum 4 4 >512 1(S) 4(S) 0,5(S) 0,125(S) >32(R)  
SaS07* Nasal 
Smear 
4 4 >512 0,5 8(R) 0,25(S) 4(R) >32(R)  
SaS08* Wound 
Smear 
4 4 >512 1(S) 4(S) >32(R) 0,5 - 1(S) >32(R)  
SaS09 Wound 
Smear 
4 4 >512 1(S) 4(S) 1(S) 1(S) >32(R)  
SaS10 Urine 4 4 >512 1(S) 4(S) 1(S) 1(S) 0,5-1(S)  
SaS11* Wound 
Smear 
4 4 >512 1(S) 4(S) 1(S) 2(R) >32(R)  
SaS12* Wound 
Smear 
4 4 >512 1(S) 4(S) 1(S) 2(R) >32(R)  
SaS13* Total 
Blood 
2 2-4 >512 0,5(S) 4(S) 1(S) 8(R) 0,5(S)  
SaS14* Wound 
Smear 
4 4 >512 0,5(S) 4(S) >32(R) 0,5(S) >32(R)  
SaS15* Total 
Blood 
4 4 >512 1(S) 4(S) 1(S) >32(R) >32(R)  
SaS16 Skin 
Smear 
4 4 >512 1(S) 4(S) 1(S) 0,5(S) >32(R)  
SaS17 Wound 
Smear 
4 4 >512 1(S) 4(S) 1(S) 8(R) 4(R)  
SaS18* Wound 
Smear 
4 4 >512 1(S) 4(S) >32(R) 4(R) 4(R)  
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Isothermal titration calorimetry curve for CAMP207 (5290 µM) vs. teichoic acids (500 µM)  
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